Joint Research Chair

Advanced Stem Cell Therapy

Regenerative medicine from the basic to clinical level
  • Application of allogeneic adipose-derived mesenchymal stromal cells for disease treatment
  • Mechanisms of cellular funtion and immune response
  • Bioengineering technologies such as cell sheets and scaffolds
  • New transplantation methods, such as minimally invasive transplantation

Allogeneic adipose-derived mesenchymal stromal cells for new clinical applications

For many tissues, such as skin and cartilage, regenerative medicine has depended on autologous cells. However, for regenerative medicine to reach industrial levels, autologous methods are not suitable. Instead, a paradigm shift that focuses on allogeneic cells is necessary. We believe that this will scale the potential of regenerative medicine greatly .

It is now possible to cultivate large amounts of adipose tissue-derived mesenchymal stromal cells (ADSCs). These cells can be cryofreezed without compromising their differentiation potential or cytokine production. We are investigating ways the clinical application of ADSCs at industrial levels.

For example, we have shown that the transplantation of ADSC improves the function of ischemic cardiomyopathy. To do so, we developed a transplantation method in which ADSCs are administered to the heart by applying techniques commonly used in cardiac surgery (patent pending). This technique involved processing the cryopreserved cells and then transplanting them a short time after (less than an hour). This method therefore has the potential for emergency surgeries.

We aim to extend the clinical application of ADSCs beyond cardiovascular surgery. At the same time, we are conducting basic research on the mechanisms of the ADSC therapeutic effect and immune responses. We are also investigating transplantation methods that are minimally invasive by collaborating with research institutions and companies.